29 Apr 2017 | Livemint.com

BSE
NSE
Last Updated: Mar 31, 03:33 PM
Kabra Drugs Ltd.

BSE

  • 6.45 -0.23 (-3.44%)
  • Vol: 1192
  • BSE Code: 524322
  • PREV. CLOSE
    6.68
  • OPEN PRICE
    6.45
  • BID PRICE (QTY.)
    6.45(58)
  • OFFER PRICE (QTY.)
    0.00(0)

NSE

  • (%)
  • Vol:
  • NSE Code:
  • PREV. CLOSE
  • OPEN PRICE
  • BID PRICE (QTY.)
    ()
  • OFFER PRICE (QTY.)
    ()

Kabra Drugs Ltd. Board Meetings

From date
To date
Source Date Board Meeting Date Details
10-Apr-201717-Apr-2017The Company informs you that a meeting of the Board of Directors will be held on 17th April, 2017, inter alia,to transact the following business: 1. To accept resignation of Mr. Rajendra Kumar Bordia, Independent Director from the Board. 2. To consider appointment of Mr. Kuldeep Kumar Ajmera, as Additional Director in the Independent non- executive Category. 3.To constitute Audit Committee by reconstituting the existing Audit Committee. 4.To constitute Nomination and Remuneration Committee by reconstituting the existing Nomination and Remuneration Committee. 5.To constitute Stakeholders Relationship Committee by reconstituting the existing Stakeholders Relationship Committee. 6.Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, which shall include at least one Independent Director, if any.
08-Feb-201714-Feb-2017 Quarterly Results
10-Nov-201614-Nov-2016 Quarterly Results & Kabra Drugs Ltd has informed BSE that the meeting of the Board of Directors of Company is scheduled to be held on November 14, 2016, inter alia, to transact the following business:- 1. To approve the Unaudited financial results and Limited Review Report of the Company for the quarter ended September 30, 2016. 2. To adopt Reconciliation of Share Capital Audit for the quarter ended September 30, 2016. 3. To take on record the Statement of Investors complaints and Shareholding Pattern for the quarter ended September 30, 2016.
11-Aug-201613-Aug-2016 Quarterly Results & Kabra Drugs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 13, 2016, inter alia, to transact the following business:- 1. To approve the Unaudited financial results of the Company for the quarter ended June 30, 2016. 2. To appoint Mr. Manish Maheshwari as Scrutinizer for the financial year 2016-17. 3. To consider sell of undertaking of the Company, subject to the approval of shareholders and to approve notice of the Postal Ballot for the same. 4. To decide date, venue and time of the Annual General Meeting. 5. To approve the Notice for calling of the Annual General Meeting. 6. To approve the Directors Report and Corporate Governance Report. 7. To fix date for closure of Register of Members and Share Transfer Books. 9. To adopt Reconciliation of Share Capital Audit for the quarter ended June 30, 2016. 10. To take on record the Statement of Investors complaints and Shareholding Pattern for the quarter ended June 30, 2016.
24-May-201628-May-2016 Audited Results & Kabra Drugs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 28, 2016, inter alia, to transact the following business:- 1. To consider and approve re-appointment of Mr. Shyam Kabra as a Managing Director for a further period of five years w.e.f. June 01, 2016. 2. To appoint Mr. Manish Maheshwari as a Secretarial Auditor for the financial year 2016- 17.
03-Feb-201613-Feb-2016Kabra Drugs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on February 13, 2016, inter alia, to transact the following business: 1. To approve the Unaudited financial results of the Company for the quarter ended December 31, 2015. 2. To delegate Board power to Stakeholders Relationship Committee to issue duplicates Share Certificates. Further, as per the Company's Code of Conduct for Prevention of Insider Trading read with Securities Exchange Board of India (Prohibition of Insider Trading) Regulation, 2015, the 'Trading window* for dealing in Equity Shares of the Company shall remain closed from February 03, 2016 to February 16, 2016 (both days inclusive) for the purpose of considering the Unaudited Financial Result of the Company for the Quarter ended on December 31, 2015. Therefore, all the Designed Employees (including Directors) of the Company have been intimated not to enter into any transaction involving the securities of the Company during the aforesaid period of closure of Trading Window. The "Trading window’ shall reopen for dealing in securities in the Equity shares of the Company from the start of the business hours on February 17, 2016.
07-Oct-201515-Oct-2015 The Board of Directors of the Company will be held on October 15, 2015, inter alia, to transact the following business: 1. To issue Duplicate Share Certificates to the shareholders. 2. To accept resignation of Mr. Ramesh Rai from the Board. 3. To constitute Audit Committee by reconstituting the existing Audit Committee. 4. To constitute Nomination and Remuneration Committee by reconstituting the existing Nomination and Remuneration Committee. 5. To constitute independent Directors Committee by reconstituting the existing Independent Directors Committee.
11-Aug-201514-Aug-2015 Quarterly Results & The Board of Directors of the Company will be held on August 14, 2015, inter alia, to transact the following business:- 1. To approve the Unaudited financial results of the Company for the quarter ended June 30, 2015. 2. To decide date, venue and time of the AnnualMeeting. 3. To approve the Notice for calling of the AnnualMeeting. 4. To fix date for closure of Register of Members and Share Transfer Books. 5. To appoint Company Secretary and Compliance Officer of the Company. 6. To appoint Internal Auditors for the Company.
29-May-201530-May-2015 The Board of Directors of the Company will be held on May 30, 2015, inter alia, to consider the following items:- 1. To take on record of Audited Financial Result of the Company for the Quarter and Financial Year ended on March 31, 2015 and to release the Audited Result to Press. 2. To Reappoint of Chief Financial Officer. 3. To appoint a Women Director of the Company. 4. To appoint an Independent Director of the Company. 5. To appoint an Independent Director of the Company. 6. To appoint Company Secretary and Compliance Officer of the Company. & Audited Results